MCK.NYSEMckesson CORP
10-Q: McKesson Reports Q3 Results: Revenue Surges, Earnings Mixed Amid Divestitures and Restructuring
Sentiment:
Quarterly Report
McKesson's Q3 results show strong revenue growth driven by the U.S. Pharmaceutical segment, but earnings are impacted by divestiture-related charges and restructuring initiatives.
Worse than expectedNet income attributable to McKesson Corporation decreased by 8% to $2.0 billion, with diluted earnings per share decreasing to $15.80 from $16.39 for the nine months ended December 31, 2024.
Summary
- McKesson Corporation reported an 18% increase in revenues for the three months ended December 31, 2024, reaching $95.3 billion, compared to $80.9 billion in the same period last year.
- Gross profit increased by 4% to $3.3 billion, while total operating expenses decreased by 18% due to factors including the sale of the Canadian retail disposal group.
- Net income attributable to McKesson Corporation increased by 49% to $879 million, with diluted earnings per share rising to $6.95 from $4.42.
- For the nine months ended December 31, 2024, revenues increased by 15% to $268.2 billion, and gross profit increased by 5% to $9.7 billion.
- However, net income attributable to McKesson Corporation decreased by 8% to $2.0 billion, with diluted earnings per share decreasing to $15.80 from $16.39.
- The company completed the sale of its Canadian retail disposal group on December 30, 2024, recognizing a $666 million charge to remeasure the assets to fair value.
- McKesson is implementing enterprise-wide restructuring initiatives expected to cost $650 million to $700 million, with $245 million in charges recorded for the nine months ended December 31, 2024.
- The company repurchased $2.8 billion of common stock and paid $254 million in dividends during the nine months ended December 31, 2024.
- McKesson is also involved in opioid-related litigation and has an estimated liability of $6.4 billion as of December 31, 2024.
- The company is acquiring Core Ventures for $2.49 billion and PRISM Vision Holdings for $850 million, pending regulatory approvals.
Sentiment
Score: 6
Explanation: The document presents a mixed sentiment. While revenue growth is positive, significant charges related to divestitures, restructuring, and opioid litigation weigh on the overall outlook. Strategic acquisitions offer potential for future growth, but integration risks remain.
Positives
- Revenue growth in the U.S. Pharmaceutical segment indicates strong market position and demand.
- The completion of the Canadian retail disposal group sale provides additional capital.
- Share repurchases and dividend payments demonstrate a commitment to returning value to shareholders.
- The company is actively pursuing strategic acquisitions to expand its business.
Negatives
- The $666 million charge related to the Canadian retail disposal group significantly impacted earnings.
- Restructuring charges of $245 million indicate ongoing operational changes and potential disruptions.
- The $6.4 billion liability for opioid-related claims represents a significant financial risk.
- Diluted earnings per share decreased to $15.80 from $16.39 for the nine months ended December 31, 2024.
Risks
- Opioid-related litigation could result in material adverse impacts on the company's financial position.
- The integration of acquired companies, such as Core Ventures and PRISM Vision Holdings, may present challenges.
- Changes in pharmaceutical pricing and regulations could affect revenue and profitability.
- The company's LIFO accounting method can result in charges due to generic deflation.
Future Outlook
The company is focused on driving operational efficiencies, increasing cost optimization efforts, and expanding its business through strategic acquisitions. However, the company faces risks related to opioid litigation, integration of acquired companies, and changes in pharmaceutical pricing and regulations.
Industry Context
McKesson's performance reflects trends in the pharmaceutical distribution industry, including market growth, generic drug conversions, and the increasing importance of specialty pharmaceuticals. The company's acquisitions and restructuring efforts are aimed at improving its competitive position and adapting to changing market conditions.
Comparison to Industry Standards
- McKesson's revenue growth of 18% in Q3 2025 is strong compared to other major pharmaceutical distributors such as Cardinal Health and AmerisourceBergen.
- Cardinal Health reported revenue growth of 12% in their most recent quarter, while AmerisourceBergen reported revenue growth of 11%.
- McKesson's focus on specialty pharmaceuticals aligns with industry trends, as this segment is experiencing higher growth rates compared to traditional pharmaceuticals.
- The company's restructuring initiatives are similar to those undertaken by other companies in the industry to improve efficiency and reduce costs.
- The opioid litigation liability is a common challenge for pharmaceutical distributors, and McKesson's $6.4 billion liability is comparable to those of its peers.
- The acquisitions of Core Ventures and PRISM Vision Holdings are strategic moves to expand McKesson's presence in the oncology and ophthalmology markets, respectively.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | NA | Lynne M. Doughtie | 2025-02-03 | Election of Director |
| Director | NA | Dr. Julie L. Gerberding | 2025-02-03 | Election of Director |
Legal Proceedings
- The Company and its affiliates have been sued as defendants in many cases asserting claims related to distribution of controlled substances, such as opioids.
- The City of Baltimore, Maryland, is one such subdivision. A trial of its claims against the Company and another national pharmaceutical distributor began on September 16, 2024 in the Circuit Court of Maryland for Baltimore City, Mayor and City Council of Baltimore v. Purdue Pharma LP, No. 24-C-18-000515 .
- On November 12, 2024, the jury returned a verdict finding the Company liable and assessing approximately $192 million in compensatory damages.
- On December 30, 2019, a group of independent pharmacies and a hospital filed a purported class action complaint alleging that the Company and other distributors violated the Sherman Act by colluding with manufacturers to restrain trade in the sale of generic drugs.
- In July 2020, the Company was served with a first amended qui tam complaint filed in the United States District Court for the Southern District of New York by a relator on behalf of the United States, 27 states and the District of Columbia against McKesson Corporation, McKesson Specialty Distribution LLC, and McKesson Specialty Care Distribution Corporation, alleging that defendants violated the Anti-Kickback Statute, federal False Claims Act, and various state false claims statutes by providing certain business analytical tools to oncology practice customers, United States ex rel. Hart v. McKesson Corporation, et al. , 15-cv-00903-RA.
Stakeholder Impact
- Shareholders will benefit from share repurchases and dividend payments.
- Employees may be affected by restructuring initiatives and headcount reductions.
- Customers will benefit from the company's efforts to improve efficiency and expand its service offerings.
- Suppliers may be affected by changes in the company's purchasing patterns.
- Communities affected by the opioid epidemic will benefit from settlement payments used for remediation efforts.
Next Steps
- The company will continue to implement its restructuring initiatives to drive operational efficiencies.
- McKesson will work to obtain regulatory approvals for the acquisitions of Core Ventures and PRISM Vision Holdings.
- The company will continue to defend itself in opioid-related litigation.
- McKesson will monitor and respond to changes in pharmaceutical pricing and regulations.
Key Dates
| Date | Description |
|---|---|
| 2016 | Company is generally subject to audit by taxing authorities in various U.S. states and in foreign jurisdictions for fiscal years 2016 through the current fiscal year. |
| 2018-04-25 | Date of qui tam complaint filed in the U.S. District Court for the Eastern District of New York. |
| 2020-07-31 | Date of first amended qui tam complaint filed in the United States District Court for the Southern District of New York. |
| 2022-11-07 | Company entered into a Credit Agreement (the 2022 Credit Facility), that provides a syndicated $4.0 billion senior unsecured credit facility with a $3.6 billion aggregate sublimit of availability in Canadian dollars, British pound sterling, and Euro. |
| 2023-06-15 | Company completed a public offering of 4.90% Notes due July 15, 2028 in a principal amount of $400 million (the 2028 Notes) and a public offering of 5.10% Notes due July 15, 2033 in a principal amount of $600 million (the 2033 Notes and, together with the 2028 Notes, the Notes). |
| 2023-06-16 | Company completed a cash tender offer for any and all of its then outstanding 2024 Notes, which was made concurrently with the offerings of the Notes (the Concurrent Tender Offer). |
| 2024-02-15 | The 2026 Notes became callable on or after February 15, 2024. |
| 2024-02-27 | Michele Lau, our Executive Vice President and Chief Legal Officer, adopted a Rule 10b5-1 trading arrangement for the sale of up to 950 shares of the Companys common stock. |
| 2024-03-12 | The U.S. Court of Appeals for the Second Circuit affirmed the dismissal of claims under the Anti-Kickback Statute and federal False Claims Act, vacated the dismissal of the remaining claims, and remanded for further proceedings. |
| 2024-06-07 | The relator filed a petition seeking review by the U.S. Supreme Court, which was denied on October 7, 2024. |
| 2024-07 | The Companys quarterly dividend was raised from $0.62 to $0.71 per share of common stock for dividends declared on or after such date by the Board. |
| 2024-07 | The Board approved an increase of $4.0 billion in the authorization for the repurchase of common stock. |
| 2024-08 | Rite Aid's restructuring plan was approved by the court and the company successfully emerged from bankruptcy in August 2024. |
| 2024-08-26 | We entered into a definitive agreement to acquire a 70% controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). |
| 2024-09-10 | Company completed a public offering of 4.25% Notes due September 15, 2029 in a principal amount of $500 million (the 2029 Notes). |
| 2024-10-07 | The relator filed a petition seeking review by the U.S. Supreme Court, which was denied on October 7, 2024. |
| 2024-10-30 | The company made a payment of $25 million for fiscal 2024 excise taxes previously accrued. |
| 2024-11-06 | We received a request for additional information and documentary materials from the Federal Trade Commission (the FTC) in connection with the FTCs review of our proposed acquisition of Core Ventures. |
| 2024-11-08 | Brian Tyler, our Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement for the sale of up to 100,774 shares of the Companys common stock. |
| 2024-11-09 | Britt Vitalone, our Executive Vice President and Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement for the sale of up to 11,133 shares of the Companys common stock. |
| 2024-11-12 | The Court of Appeals for the Second Circuit affirmed the dismissal of claims under the Anti-Kickback Statute and federal False Claims Act. |
| 2024-11-12 | The jury returned a verdict finding the Company liable and assessing approximately $192 million in compensatory damages. |
| 2024-11-26 | Michele Lau, our Executive Vice President and Chief Legal Officer, adopted a Rule 10b5-1 trading arrangement for the sale of up to 950 shares of the Companys common stock. |
| 2024-11-27 | The Company placed approximately $149 million into escrow on November 27, 2024. |
| 2024-12-30 | Company completed the sale of its Rexall and Well.ca businesses in Canada (Canadian retail disposal group). |
| 2025-01 | Company also paid $15 million in January 2025 and additionally will pay approximately $84 million through 2033. |
| 2025-01-15 | The U.S. District Court for the Northern District of Ohio overruled objections to the settlement and granted final approval to the settlement. |
| 2025-02-03 | The district court granted distributor defendants motion to dismiss the complaint with prejudice. |
| 2025-02-03 | The Board elected Lynne M. Doughtie and Dr. Julie L. Gerberding as directors, each effective February 3, 2025. |
| 2025-02-04 | Company entered into a definitive agreement to acquire a controlling interest in PRISM Vision Holdings (PRISM Vision). |
| 2025-02-15 | The effective date of the settlement will be February 15, 2025 if no party appeals or files a motion for reconsideration. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.